<DOC>
	<DOCNO>NCT00801229</DOCNO>
	<brief_summary>The primary objective study assess benefice Vyvanse factor cause impairment drive behavior individual ADHD use drive simulation aim examine factor cause impairment drive behavior individual ADHD drive speed , collision risk , visual attention 60 young driver ( age 18-24 ) ADHD . We hypothesize : 1 . ) young adult ADHD treat Vyvanse show low velocity ( speed ) score spend less time drive post speed limit drive simulation compare subject take placebo ; 2 . ) young adult ADHD treat Vyvanse show lesser likelihood collide suddenly appear peripheral object , less difficulty maintain vehicle within lane , less likelihood drive stop sign solid red traffic light without slow compare subject take placebo ; 3 . ) young adult ADHD treat Vyvanse exhibit focus visual attention detail visual field compare subject take placebo driving . In addition , young adult ADHD treat Vyvanse exhibit less visual tunneling short off-road glance compare subject take placebo .</brief_summary>
	<brief_title>Effect Vyvanse Driving Young Adults With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Male female outpatient , age 1824 year . Subjects meet full criterion diagnosis DSMIV Attention Deficit Hyperactivity Disorder ( ADHD ) , onset symptom childhood persistence impairing symptom adulthood determine clinical evaluation and/or ADHD module structure diagnostic interview , complete study clinician . Absence pharmacological treatment ADHD past month . Any current psychiatric medical condition determine clinically significant . Current use psychotropics medication clinically significant CNS effect . Individuals never hold valid driver 's license . Mental retardation ( IQ &lt; 80 ) . Individuals history substance dependence abuse within past 6 month . Pregnant nursing female . Known hypersensitivity Vyvanse amphetamine . Subjects preexist structural cardiac abnormality . Clinically significant abnormal screen value include : Laboratory value determine clinically significant . Consistent reading hypertension ( &gt; 140/90 ) screening period ( include screen baseline visit ) , define two reading ( average three measurement ) single visit systolic blood pressure , SBP &gt; 140 and/or diastolic blood pressure , DBP , &gt; 90 , confirm manual reading . Subjects isolated incidence ( triplicate average BP ) SBP &gt; 140 and/or DBP &gt; 90 baseline/week 0 visit , confirm manual reading , determine clinically significant . Subjects clinically significant abnormality accord cardiology consultation ( ECGs clinically concern interval include PR , QTC , QRS , review cardiology ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>ADHD</keyword>
	<keyword>young adult</keyword>
	<keyword>drive</keyword>
	<keyword>Vyvanse</keyword>
	<keyword>lisdexamfetamine</keyword>
</DOC>